RYFAX-500 TAB MANUFACTURERS SUPPLIERS - THIRD PARTY CONTRACT MANUFACTURING
CEFRUROXIME 500 MG
Cefuroxime is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime and other antibacterial drugs, cefuroxime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi. Cefuroxime is the prodrug.
Absorption: It is absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
Protein Binding: 50% to serum protein.
Metabolism: The moiety is metabolized to acetaldehyde and acetic acid.
Half Life: Its half life is Approximately 80 minutes following intramuscular or intravenous injection.
Acute Bacterial Otitis Media,
Urinary Tract Infections, Gonorrhea and Lyme disease (erythema migrans).